Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
ADOCIA logo — "Innovative medicine for everyone, everywhere"​

ADOCIA

"Innovative medicine for everyone, everywhere"​

Founded 2005 France France 92 employees Post-IPO Equity Total: $41.73M Biotechnology, Health and Wellness

General Information

Company Name ADOCIA
Founded Year 2005
Location France France
Employees 92
Industries Biotechnology, Health and Wellness
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with ADOCIA. To contact ADOCIA, visit adocia.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About ADOCIA

Adocia is a clinical-stage biotech company focused on developing groundbreaking medications using innovative formulations of already-approved therapeutic proteins. Specializing in diabetes and obesity, the France-based company was founded in 2005 and is listed on the Euronext stock market. Adocia's proprietary BioChaperone® platform aims to optimize the effectiveness, safety, and convenience of therapeutic proteins for patients. Their recent €9.73M post-IPO equity investment on 26 February 2025 involved contributions from Vester Finance, Gérard Soula, and Armistice Capital. Boasting the slogan "Innovative medicine for everyone, everywhere," Adocia is making significant strides in the biotechnology and health and wellness industries. More information can be found on their website: www.adocia.com. For career opportunities, the company encourages individuals to visit: https://www.adocia.com/careers/adocia-careers/.

Taxonomy: Clinical-stage, Medicine R&D, Therapeutic proteins, Diabetes treatment, Obesity treatment, BioChaperone® platform, Protein formulations, Cell therapy, Islet transplantation, Metabolic diseases, Injectable formulations, Ultra-rapid Insulin, GLP-1, Amylin

Services & Products

Biotechnology research and development
product formulation
technology licensing

Target Customers

Patients with diabetes and obesity pharmaceutical companies research institutions healthcare professionals

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity €9.73M 3
Vester Finance, Gérard Soula +1
26 Feb 2025
Post IPO Debt €6.00M -
26 Oct 2021
Series B €14.00M 2
IDInvest Partners
IDInvest Partners, CDC Enterprises
27 Jan 2010
Venture Round €12.00M 4
IDInvest Partners Bioam Gestion
IDInvest Partners, Bioam Gestion +2
21 Jan 2008

Latest News

View All
MaaT Pharma obtient un financement de près de 40 millions d’euros avec la BEI, une excellente nouvel... — Investir.lesechos.fr
MaaT Pharma obtient un financement de près de 40 millions d’euros avec la BEI, une excellente nouvelle pour les développements prometteurs de la biotech
Investir.lesechos.fr Jul 29, 2025
Maat Pharma signe avec Clinigen pour la distribution de son traitement Xervyteg en Europe — Investir.lesechos.fr
Maat Pharma signe avec Clinigen pour la distribution de son traitement Xervyteg en Europe
Investir.lesechos.fr Jul 03, 2025
Maat Pharma : nouveau médicament en 2026 — Investir.lesechos.fr
Maat Pharma : nouveau médicament en 2026
Investir.lesechos.fr Jun 25, 2025
Derrière l'envolée boursière de Maat Pharma se cache sa percée dans la lutte contre la maladie aigüe... — Investir.lesechos.fr
Derrière l'envolée boursière de Maat Pharma se cache sa percée dans la lutte contre la maladie aigüe du greffon contre l'hôte
Investir.lesechos.fr Jan 09, 2025
Maat Pharma lève plus de 19 millions d’euros pour financer ses recherches — Investir.lesechos.fr
Maat Pharma lève plus de 19 millions d’euros pour financer ses recherches
Investir.lesechos.fr May 15, 2024

ADOCIA Alternatives & Competitors

View All Alternatives
ADOCIA vs
Orgenesis Inc.
Orgenesis Inc. United States

Unlocking the Potential of Cell and Gene Therapy for All (NASDAQ: ORGS)

Grant
65 employees
Biotechnology, Health Care
ADOCIA vs
ViaCyte
ViaCyte United States

Regenerating Health: Transforming the lives of patients with insulin-requiring diabetes

Series D
35 employees
Biotechnology, Health Care
ADOCIA vs
MeiraGTx
MeiraGTx United Kingdom

Engineering Hope

IPO
419 employees
Biotechnology, Health Care
View all alternatives

FAQ About ADOCIA

"Innovative medicine for everyone, everywhere"​
ADOCIA was founded in 2005.
ADOCIA is headquartered in France.
ADOCIA operates in Biotechnology and Health and Wellness. Its work centres on Clinical-stage, Medicine R&D, Therapeutic proteins and Diabetes treatment. Its customers include Patients with diabetes and obesity, pharmaceutical companies and research institutions.
ADOCIA has approximately 92 employees.
ADOCIA has completed 4 funding rounds, raising a total of $41.73M. The latest funding stage is Post-IPO Equity.
ADOCIA offers: Biotechnology research and development, product formulation, technology licensing.
Top alternatives and competitors to ADOCIA include Orgenesis Inc., ViaCyte, MeiraGTx, Diasome Pharmaceuticals, Inc., Scarlet Therapeutics Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ADOCIA and Orgenesis Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ADOCIA, https://bouncewatch.com/company/adocia, updated 11 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes